Cynomolgus CD30 Ligand / TNFSF8 Protein (His Tag) (Cytokine)

Sino Biological Inc. liefert Cynomolgus CD30 Ligand / TNFSF8 Protein (His Tag) (Cytokine) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Cynomolgus CD30 Ligand / TNFSF8 Protein (His Tag) (Cytokine) lesen Sie bitte: http://www.sinobiological.com/CD153-CD30L-TNFSF8-Protein-a-440.html

Produkt-Information von CD30 Ligand / TNFSF8 Protein

QC Testing von CD30 Ligand / TNFSF8 Protein

Purity	> 95 % as determined by SDS-PAGE	SDS-PAGE: TNFSF8 protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	His
Molecular Mass	The recombinant heterodimer of cynomolgus TNFSF8 comprises 192 amino acids and has a calculated molecular mass of 22 KDa. The apparent molecular mass of the protein is approximately 38 KDa respectively in SDS-PAGE.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von CD30 Ligand / TNFSF8 Protein

Verwandte Produkte & Themen von CD30 Ligand / TNFSF8 Protein

Beschreibung von CD30 Ligand / TNFSF8 Protein

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a cytokine belonging to the emerging tumor necrosis factor (TNF) ligand superfamily, and is a specific ligand for CD30/ TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response.

References

1. Gruss HJ. et al.,1994, Blood. 83: 2045-56.
2. Croager EJ. et al., 1997, Biochim Biophys Acta. 1353: 231-5.
3. Wendtner CM. et al., 1995, Cancer Res. 55: 4157-61.
4. Fischer M. et al., 2006, J Clin Invest. 116: 2748-56.
5. Blazar BR. et al., 2004, J Immunol. 173: 2933-41.

• What is Cytokine
• Cytokine Production
• Cytokine Signaling
• Cytokine Storm
• Cytokine Therapy
• Inflammatory Cytokines